Video overview of alopecia areata and potential treatment options in development

July 14th, 2021

In this video, Dr. James Cassella, Concert’s Chief Development Officer, gives an overview of alopecia areata and discusses potential new treatments in development, including CTP-543.

CTP-543, an oral selective inhibitor of Janus kinases JAK1 and JAK2, is in clinical development for the treatment of moderate to severe alopecia areata. CTP-543 is an investigational drug and has not been approved by the FDA or any regulatory authority for any use.

Back to Top